Alzheon Investigates Subgroup Data Following Phase 3 Trial of ALZ-801 in Alzheimer’s Disease

Alzheimer’s disease , ALZ-801 , Valiltramiprosate , APOE4 genotype , Mild cognitive impairment (MCI) , Amyloid-targeting therapy , Phase 3 trial results , Cognitive decline , Subgroup analysis , Precision medicine

Truveta Genome Project: A Historic 10M Genome Sequencing Initiative Backed by Regeneron, Illumina, and Leading Health Systems

Truveta Genome Project, 10M genome sequencing, Regeneron, Illumina, genetic sequencing, genotypic and phenotypic data, healthcare analytics, drug discovery, personalized medicine.